Background. The ability to noninvasively assess arterial CD206 + macrophages may lead to improved understanding of human immunodeficiency virus (HIV)-associated cardiovascular disease.
Methods. We trialed a novel macrophage-specific arterial imaging technique.
Results. We demonstrated colocalization between technetium Tc 99m tilmanocept ( Tc-tilmanocept uptake across 20.4% of the aortic surface volume among HIV-infected subjects, compared with 4.3% among non-HIV-infected subjects (P = .009). Among all subjects, aortic high-level 99m Tc-tilmanocept uptake was related to noncalcified aortic plaque volume (r = 0.87; P = .003) on computed tomographic angiography, and this relationship held when we controlled for HIV status.
Conclusion. These first-in-human data introduce a novel macrophage-specific arterial imaging technique in HIV.
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Individuals with human immunodeficiency virus (HIV) infection have an increased risk of myocardial infarction [1, 2] , thought to be fueled in part by heightened systemic immune activation [3] and downstream arterial inflammation [4, 5] . Development of targeted immunomodulatory strategies to reduce myocardial infarction risk in HIV requires improved understanding of the relationship between systemic immune activation, arterial inflammation, and atherogenesis/plaque remodeling. We previously assessed aortic fluorodeoxyglucose labeled with fluorine 18 ( 18 F-FDG) uptake seen with positron emission tomography (PET)/computed tomography (CT) as a proxy for arterial inflammation, showing increased uptake in HIV-infected individuals compared with matched controls [6] . However, the 18 F-FDG PET/CT technique has limitations: although arterial 18 F-FDG uptake on PET/CT tends to track with the number of arterial macrophages [7] , it reflects the presence of metabolically active cells and not macrophages per se. More specifically, noninvasive molecular techniques are needed to functionally image arterial inflammation in HIV infection.
We tested the degree of colocalization between the radiopharmaceutical technetium Tc 99m tilmanocept ( 99m Tc-tilmanocept) and CD206 + macrophages in tissue-banked aortic samples of individuals with or without HIV infection. Next, we performed a first-in-human assessment of whether systemic Tc-tilmanocept ( 99m Tc-diethylenetriaminepentaacetic acidmannosyldextran) was synthesized to avidly and specifically bind the macrophage mannose receptor, CD206 [8, 9] . This radiopharmaceutical consists of a dextran backbone supporting amine-terminated molecular leashes, which link with mannose moieties (permitting CD206 binding) and moieties of diethylenetriaminepentaacetic acid (permitting labeling with 99m Tc) [8, 9] (Supplemental Figure 1) . Injected peritumorally or intradermally, 99m Tc-tilmanocept has proved useful for preoperative detection of tumor-affected lymph nodes in patients with head and neck cancer [10] , breast cancer [11] , and melanoma [11] . We hypothesized that subcutaneous administration of 99m Tc-tilmanocept would permit SPECT/CT-based quantification of its aortic uptake.
METHODS

Ex Vivo Experiments on Tissue-Banked Aortic Samples From Individuals
With or Without HIV
Aortic samples from individuals with (n = 10) or without (n = 10) HIV infection were obtained from the National NeuroAIDS Tissue Consortium and National Disease Research Institute. The density of aortic CD206 macrophage infiltration was compared, and the degree of colocalization of tilmanocept-positive and CD206 + macrophages assessed (Supplemental Methods).
Human Subjects Study
Study Design
Six HIV-infected subjects were recruited and enrolled. Major entry criteria included age ≥18 years, documented HIV infection, current use of antiretroviral therapy without regimen changes within the last 3 months, and subclinical atherosclerosis at CT angiography. Major exclusion criteria included known current or prior clinical cardiovascular disease, current treatment with prescription systemic steroids or anti-inflammatory/immunosuppressant medical therapies, any recent statin therapy, and estimated glomerular filtration rate <60 mL/min/1.73 m 2 . Subsequently, for comparison, non−HIV-infected subjects without known current or prior clinical cardiovascular disease were recruited. Seven non− HIV-infected subjects were screened to enroll 3 with cardiovascular risk profiles (sex, age, and Framingham risk score) similar to those in the HIV-infected group. These subjects did not have prior CT angiographic data available, but all 3 demonstrated subclinical atherosclerosis at the CT angiography performed as part of the study. Subjects underwent Tc-tilmanocept dose of <2 mCi (50 μg) (1.37-1.85 mCi) was injected subcutaneously by a physician trained in nuclear medicine. The dose range was derived by subtracting the residual radioactivity in the syringe post injection from the total radioactivity in the syringe prior to injection. The subcutaneous route was chosen because it is a Food and Drug Administration-approved route of administration for this radiopharmaceutical, albeit for a different indication. For details on imaging technique and analysis, see Supplemental Methods. In brief, muscle was chosen as an analytic reference region, owing to low and consistent activity across subjects and groups, to control for nonspecific tissue and blood-pool uptake. For each subject, tilmanocept activity (uptake) was normalized to a mean muscle activity of 1. A CT-guided volume of interest was drawn to cover the entirety of the aorta visible in the SPECT field of view (aortic root, arch, descending aorta to the liver base). To assure specificity of aortic analyses, "highlevel" tilmanocept uptake was defined as any voxel with activity (uptake) at ≥5 times muscle activity. This level of tilmanocept uptake was roughly equivalent to the mean activity observed in the liver (Supplemental Figure 2) . For each subject, we calculated the total volume within the aortic volume of interest that was at or above the "high-level" activity threshold, along with the percentage of the total volume at or above that level.
CT Angiography
CT angiography of the coronary arteries and thoracic aorta was performed with a Somatom Definition Flash 128-slice dual-source CT scanner (Siemens Medical Solutions), according to Society of Cardiac Computed Tomography guidelines [12] (Supplemental Methods). Techniques for assays and flow cytometric analyses are described in the Supplemental Methods.
Statistical Analysis
For ex vivo experiments, t tests were used. For the human study, the primary end point was aortic 99m Tc-tilmanocept uptake at SPECT/CT. Our initial goal was to determine feasibility of 99m Tc-tilmanocept uptake and CT angiographic/ metabolic/immune parameters were assessed using Pearson or Spearman correlation coefficients, as appropriate. Statistical tests were 2 sided and performed using JMP software (version 11; SAS Institute).
RESULTS
Ex Vivo Experiments on Tissue-Banked Aortic Samples From Individuals
With or Without HIV Infection
The mean number of CD206 + macrophages was significantly higher in aortic sections from individuals with HIV infection than in those from individuals without HIV infection (mean 
Human Subjects Study
Baseline Cardiometabolic Parameters
Study subjects were men with a mean (SD) age of 58 (8) years. No subject received statin therapy within 1 year of the study. The Framingham risk score did not differ significantly between groups (9% for HIV vs 8% for non-HIV; P = .55). Among HIVinfected subjects, the mean (SD) duration since HIV diagnosis was 23.3 (8.1) years, the median log 10 viral load was 1.4 copies/ mL (IQR, 1.3-2.8 copies/mL), and the mean (SD) CD4 + cell count was 534/μL (138/μL) (Supplemental Table 1 ).
Areas of 99m
Tc-Tilmanocept Uptake at SPECT/CT Among all subjects, significantly increased 99m Tc-tilmanocept uptake (relative to muscle) was visualized in the kidneys, liver, and aorta (Supplemental Figure 2) . Noncalcified Aortic Plaque Volume, mm3
Figure 1. Ex vivo experiments on tissue-banked aortic samples from individuals with or without human immunodeficiency virus (HIV) infection and in vivo aortic high-level technetium Tc 99m tilmanocept ( 99m
Tc-tilmanocept) uptake and relationship to aortic noncalcified plaque in both groups of subjects. A, In tissue-banked aortic samples, the mean number of CD206 + macrophages per square millimeter was significantly higher among HIV-infected individuals (n = 10) than among non−HIV-infected individuals (n = 10) (P = .0002). B, Double-label immunofluorescence using a CD206 antibody and tilmanocept-Alexa Fluor 488 revealed a high and similar degree of colocalization of tilmanocept and CD206 in sections from HIV-infected (n = 10) and non−HIV-infected (n = 10) subjects (mean [standard deviation (SD)], 89.1% [6.3%] vs 86.3% [6.8%], respectively). The mean (SD) percentages of CD206 + tilmanocept-negative macrophages and CD206 − tilmanocept-positive macrophages in HIV-infected (n = 10) versus non−HIV-infected (n = 10) subjects were 7.8% (7.0%) versus 10.4% (6.2%) and 3.1% (1.8%) versus 3.3% (2.1%), respectively. C, Aortic volume with high-level 99m Tc-tilmanocept uptake was significantly increased in HIV-infected (n = 6) compared with non−HIV-infected (n = 3) subjects (P = .03). Results represent medians and interquartile ranges, with whiskers showing minimum and maximum values. Aortic volume with high-level 99m Tc-tilmanocept uptake is shown to facilitate assessment of the relationship with total noncalcified coronary atherosclerotic plaque volume. The percentage of aortic volume with high-level 99m Tc-tilmanocept uptake was significantly increased among HIV-infected (n = 6) compared with non−HIV-infected (n = 3) subjects (P = .009). Results represent means with SDs. D, Regression analysis demonstrating a significant relationship between aortic volume with high-level 99m Tc-tilmanocept uptake at single-photon emission computed tomography/computed tomography and noncalcified aortic plaque volume (Pearson correlation coefficient [r] = 0.87; P = .003). HIV-infected subjects (n = 6) are represented as triangles, and non−HIV-infected control subjects (n = 3) as squares.
significant relationship between aortic volume with high-level 99m Tc-tilmanocept uptake and noncalcified aortic atherosclerotic plaque volume (r = 0.87; P = .003), and this relationship held when HIV status was controlled for (overall model, R 2 = 0.76; overall P = .01; P = .02 for noncalcified plaque volume; Figure 1D ).
Aortic 99m
Tc-Tilmanocept Uptake in Relation to Immune Phenotype HIV-infected subjects, in general, had higher levels of systemic monocyte activation markers, as well as higher absolute numbers of monocyte subsets, higher absolute CD8 + T-cell counts, and relatively lower absolute CD4 + T-cell counts (Supplemental Table 3 ). Among all subjects, aortic volume with high-level 99m Tc-tilmanocept uptake related to levels of soluble CD14 (P = .72; P = .03), absolute number of CD14 + CD16
− monocytes (P = .77; P = .02), absolute CD8 + T-cell count (P = .73; P = .02), and absolute CD8 + PD1 + T-cell count (P = .70; P = .04). In analogous univariate analyses performed separately among HIV-infected and non−HIV-infected subjects, relationships between these systemic immune parameters and aortic volume of high-level 99m Tc-tilmanocept uptake did not achieve statistical significance.
DISCUSSION
We present first-in-human data applying a novel CD206 + macrophage-specific arterial imaging strategy, Tc-tilmanocept uptake relates robustly to noncalcified aortic atherosclerotic plaque volume, even after controlling for HIV status, highlighting a potential link between arterial CD206 + macrophage density and atherogenesis.
Recent research lends biologic plausibility to the hypothesis that CD206
+ macrophages, such as those tagged by 99m
Tc-tilmanocept, are relevant to atherogenesis. Indeed, analysis of coronary artery sections from sudden cardiac death victims has revealed that CD206 + macrophages are particularly abundant in "unstable" thin-capped fibroatheromas [13] . The traditional macrophage classification paradigm (developed from in vitro studies) sorts CD206 + macrophages into the M2 phenotype-an "alternatively activated" class working to counterbalance the proinflammatory effects of "classically activated" M1 macrophages. However, macrophage behavior in vivo defies rigid classification. Significant heterogeneity exists within the canonical M1/M2 macrophage categories, including, for example, a subclass of M2 macrophages, M2b, producing high-levels of proinflammatory cytokines [14] . Moreover, macrophages demonstrate plasticity in vivo, switching phenotypes in response to locally encountered microenvironmental cues [14] . Our findings suggest a greater relative abundance of CD206 + macrophages in the aortas of HIV-infected versus non−HIV infected individuals, and further highlight a relationship between aortic high-level tilmanocept uptake and aortic noncalcified atherosclerotic plaque. Further research is needed to elucidate whether arterial CD206 + macrophages contribute to or compensate for in situ arterial inflammation/atherogenesis in HIV infection.
Recognizing the potential importance of CD206 + (mannose receptor-bearing) macrophages to atherogenesis, Tahara et al [13] Tc-tilmanocept SPECT/CT are required to establish the relative merits of each technique, including sensitivity and specificity for quantifying arterial CD206 + macrophage infiltration in humans. This proof-of concept study has limitations, including lack of aortic tissue from the same human subjects who underwent in vivo 99m Tc-tilmanocept SPECT/CT and a small sample size (precluding intragroup analyses of correlations between aortic high-level tilmanocept uptake and systemic immune parameters). Study strengths include the first-in-human application of a novel, noninvasive molecular imaging technique targeting CD206 + arterial wall macrophages. This technique may be usefully applied in larger cohorts to provide insights into specific systemic inflammatory pathways promoting in situ arterial inflammation and atherogenesis in HIV infection and to track arterial responses to targeted systemic anti-inflammatory therapies.
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